Abstract
Abstract: SPR1NT (NCT03505099) was a Phase III, multicenter, single-arm study to investigate the efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelic SMN1 mutations treated at ≤6 weeks of life. Here, we report final results for 14 children with two copies of SMN2, expected to develop spinal muscular atrophy (SMA) type 1. Efficacy was compared with a matched Pediatric Neuromuscular Clinical Research natural-history cohort (n = 23). All 14 enrolled infants sat independently for ≥30 seconds at any visit ≤18 months (Bayley-III item #26; P < 0.001; 11 within the normal developmental window). All survived without permanent ventilation at 14 months as per protocol; 13 maintained body weight (≥3rd WHO percentile) through 18 months. No child used nutritional or respiratory support. No serious adverse events were considered related to treatment by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for children expected to develop SMA type 1, highlighting the urgency for universal newborn screening.
| Original language | English |
|---|---|
| Pages (from-to) | 1381-1389 |
| Number of pages | 9 |
| Journal | Nature medicine |
| Volume | 28 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2022 |
Fingerprint
Dive into the research topics of 'Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1 : the Phase III SPR1NT trial. / Strauss, Kevin A.; Farrar, Michelle A.; Muntoni, Francesco et al.
In: Nature medicine, Vol. 28, No. 7, 07.2022, p. 1381-1389.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1
T2 - the Phase III SPR1NT trial
AU - Strauss, Kevin A.
AU - Farrar, Michelle A.
AU - Muntoni, Francesco
AU - Saito, Kayoko
AU - Mendell, Jerry R.
AU - Servais, Laurent
AU - McMillan, Hugh J.
AU - Finkel, Richard S.
AU - Swoboda, Kathryn J.
AU - Kwon, Jennifer M.
AU - Zaidman, Craig M.
AU - Chiriboga, Claudia A.
AU - Iannaccone, Susan T.
AU - Krueger, Jena M.
AU - Parsons, Julie A.
AU - Shieh, Perry B.
AU - Kavanagh, Sarah
AU - Tauscher-Wisniewski, Sitra
AU - McGill, Bryan E.
AU - Macek, Thomas A.
N1 - Funding Information: The authors wish to thank the investigators, site coordinators and study teams, administrators of newborn screening programs, and most importantly, the patients, families, and caregivers for their participation in these studies. The authors also thank M. Milton of Novartis Institutes for BioMedical Research, who provided critical review and input on content related to biodistribution, immune response, and safety; S. P. Reyna, who provided critical review and input on care of patients with SMA; and M. Wolf of Novartis Gene Therapies, who provided functional outcome measure expertise and contributions to study conduct and oversight. Medical writing assistance and editorial support was provided by M. Heitzer of Kay Square Scientific, and M. Nissen, of Novartis Gene Therapies. This support was funded by Novartis Gene Therapies. The NSW Pilot NBS study was funded by Luminesce Alliance, a not-for-profit cooperative joint venture across the Sydney Children’s Hospital Network, Children’s Medical Research Institute, and Children’s Cancer Institute, established with the support of the NSW Government. Luminesce Alliance is also affiliated with UNSW Sydney and The University of Sydney. The SPR1NT study was designed and funded by Novartis Gene Therapies, Inc., which was involved in the study design, data collection, data analysis, data interpretation, and writing of all related reports and publications. Novartis Gene Therapies, Inc., sponsored this study. Funding Information: The authors wish to thank the investigators, site coordinators and study teams, administrators of newborn screening programs, and most importantly, the patients, families, and caregivers for their participation in these studies. The authors also thank M. Milton of Novartis Institutes for BioMedical Research, who provided critical review and input on content related to biodistribution, immune response, and safety; S. P. Reyna, who provided critical review and input on care of patients with SMA; and M. Wolf of Novartis Gene Therapies, who provided functional outcome measure expertise and contributions to study conduct and oversight. Medical writing assistance and editorial support was provided by M. Heitzer of Kay Square Scientific, and M. Nissen, of Novartis Gene Therapies. This support was funded by Novartis Gene Therapies. The NSW Pilot NBS study was funded by Luminesce Alliance, a not-for-profit cooperative joint venture across the Sydney Children’s Hospital Network, Children’s Medical Research Institute, and Children’s Cancer Institute, established with the support of the NSW Government. Luminesce Alliance is also affiliated with UNSW Sydney and The University of Sydney. The SPR1NT study was designed and funded by Novartis Gene Therapies, Inc., which was involved in the study design, data collection, data analysis, data interpretation, and writing of all related reports and publications. Novartis Gene Therapies, Inc., sponsored this study. Funding Information: Novartis Gene Therapies, Inc., sponsored this clinical trial. The authors declare the following competing interests: K.A.S. has received personal compensation from Novartis Gene Therapies, Inc., (formerly AveXis) for serving as an advisory board member and from Biogen for serving as a visiting professor; and has received research support from Novartis Gene Therapies Inc., and Biogen-sponsored clinical trials. M.A.F. has received honoraria for scientific advisory boards from Novartis Gene Therapies, Inc., Biogen, and Roche, and research grants from Biogen. F. M. reports grants and personal fees from Novartis Gene Therapies, Inc., including participation in the STR1VE-EU grant and the SPR1NT study; grants, personal fees, and other (participation in the SHINE clinical trial and principal investigator of the investigator-initiated UK SMA REACH UK registry) from Biogen; and grants and personal fees from Roche, including participation in the JEWELFISH clinical trial of risdiplam and participation in the olesoxime clinical trial, during the conduct of the study. He has received honoraria for scientific advisory boards from Biogen, Novartis, Novartis Gene Therapies, Inc., PTC, Roche, and Sarepta. K. S. has served on advisory boards for Biogen, Novartis Gene Therapies, Inc., Novartis, and Chugai (Roche), and has received research funding from Biogen. J. R. M. has received personal compensation for clinical trial consulting and for serving on scientific advisory boards, as well as research support,from Novartis Gene Therapies, Inc. L.S. has received personal compensation as an advisory committee board member/consultant from Novartis Gene Therapies, Inc., Biogen, Biophytis, Cytokinetics, Dynacure, Roche, Santhera, and Sarepta Therapeutics, and has received research support from Novartis Gene Therapies, Inc., Biogen, Dynacure, and Roche. H. J. M. has received honoraria for scientific advisory boards from Novartis Gene Therapies, Inc., and research funding from Roche. R. S. F. has received personal compensation for consulting for advisory board participation from Novartis Gene Therapies, Inc., Biogen, Roche, and Scholar Rock, and for consulting from Novartis; editorial fees from Elsevier for co-editing a neurology textbook; license fees from the Children’s Hospital of Philadelphia; research funding from Novartis Gene Therapies, Inc., Biogen, Roche/Genentech, and Scholar Rock. K. J. S. has received personal compensation for a speaking engagement from Biogen, and research funding as a principal investigator for clinical trials sponsored by Novartis Gene Therapies, Inc., and Biogen. J. M. K. (Kwon) was her site’s principal investigator for clinical trials sponsored by Novartis Gene Therapies, Inc., Biogen, and Scholar Rock. C. M. Z. has received research support from Biogen. C. A. C. has served on advisory boards for Novartis Gene Therapies, Inc., Genentech, and Roche; served as an educational speaker for Biogen, and has received research funding from Novartis Gene Therapies, Inc., Biogen, and Roche. S. T. I. has received personal compensation for service on advisory boards or consulting from Novartis Gene Therapies, Inc., Biogen, Roche-Genetech, and Sarepta; and research support from Novartis Gene Therapies, Inc., Biogen, Capricor, PTC, Scholar Rock, and Sarepta. J. M. K. (Krueger) is a principal investigator for clinical trials sponsored by Novartis Gene Therapies, Inc., Scholar Rock, and Genentech-Roche. J. A. P. has served as an investigator on clinical trials for Biogen, Novartis, PTC Therapeutics, and Scholar Rock, and has served in advisory capacity for Biogen, Scholar Rock, Genentech Roche, and Novartis. P. B. S. has served as a consultant for Alexion, Biogen, Genentech, Novartis Gene Therapies, Inc., and Sarepta, and has served as a speaker for Alexion, Biogen, Genentech, Grifols, Novartis Gene Therapies, Inc., and PTC Therapeutics. S. K. is an employee of Novartis Gene Therapies, Inc., and receives consulting fees from UCB Pharma, Karuna Therapeutics, Worldwide Clinical Trials, CPC Clinical Research, Zosano Pharmaceuticals, PharPoint Research, and Nesos. S. T.-W. is an employee of Novartis Gene Therapies, Inc., and owns Novartis stock or other equities. B.E.M. is an employee of Translational Medicine, Novartis Institutes for BioMedical Research (Cambridge) and owns Novartis stock or other equities. T.A.M. is an employee of Novartis Gene Therapies, Inc., and owns Novartis stock or other equities. Publisher Copyright: © 2022, The Author(s).
PY - 2022/7
Y1 - 2022/7
N2 - Abstract: SPR1NT (NCT03505099) was a Phase III, multicenter, single-arm study to investigate the efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelic SMN1 mutations treated at ≤6 weeks of life. Here, we report final results for 14 children with two copies of SMN2, expected to develop spinal muscular atrophy (SMA) type 1. Efficacy was compared with a matched Pediatric Neuromuscular Clinical Research natural-history cohort (n = 23). All 14 enrolled infants sat independently for ≥30 seconds at any visit ≤18 months (Bayley-III item #26; P < 0.001; 11 within the normal developmental window). All survived without permanent ventilation at 14 months as per protocol; 13 maintained body weight (≥3rd WHO percentile) through 18 months. No child used nutritional or respiratory support. No serious adverse events were considered related to treatment by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for children expected to develop SMA type 1, highlighting the urgency for universal newborn screening.
AB - Abstract: SPR1NT (NCT03505099) was a Phase III, multicenter, single-arm study to investigate the efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelic SMN1 mutations treated at ≤6 weeks of life. Here, we report final results for 14 children with two copies of SMN2, expected to develop spinal muscular atrophy (SMA) type 1. Efficacy was compared with a matched Pediatric Neuromuscular Clinical Research natural-history cohort (n = 23). All 14 enrolled infants sat independently for ≥30 seconds at any visit ≤18 months (Bayley-III item #26; P < 0.001; 11 within the normal developmental window). All survived without permanent ventilation at 14 months as per protocol; 13 maintained body weight (≥3rd WHO percentile) through 18 months. No child used nutritional or respiratory support. No serious adverse events were considered related to treatment by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for children expected to develop SMA type 1, highlighting the urgency for universal newborn screening.
UR - http://www.scopus.com/inward/record.url?scp=85132253340&partnerID=8YFLogxK
U2 - 10.1038/s41591-022-01866-4
DO - 10.1038/s41591-022-01866-4
M3 - Article
C2 - 35715566
AN - SCOPUS:85132253340
SN - 1078-8956
VL - 28
SP - 1381
EP - 1389
JO - Nature Medicine
JF - Nature Medicine
IS - 7
ER -